These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32710904)

  • 21. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
    Ravisé A; Cameau E; De Abreu G; Pralong A
    Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The state of biopharmaceutical manufacturing.
    Molowa DT; Mazanet R
    Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
    Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
    Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-Based Quality and Compliance Management in Clinical Trials with Combination Products in Changing Global Regulatory Environment.
    Kaliaev AO; Malikova MA
    Ther Innov Regul Sci; 2020 Jul; 54(4):803-813. PubMed ID: 32557305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
    Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
    J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.
    Higgins MF; Abu-Absi N; Gontarz E; Gorr IH; Kaiser K; Patel P; Ritacco F; Sheehy P; Thangaraj B; Gill T
    Biotechnol Prog; 2023 Mar; 39(2):e3321. PubMed ID: 36546782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biopharmaceuticals from microorganisms: from production to purification.
    Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
    Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-839. PubMed ID: 28756845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data integrity within the biopharmaceutical sector in the era of Industry 4.0.
    Alosert H; Savery J; Rheaume J; Cheeks M; Turner R; Spencer C; S Farid S; Goldrick S
    Biotechnol J; 2022 Jun; 17(6):e2100609. PubMed ID: 35318814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drift, evolution, and divergence in biologics and biosimilars manufacturing.
    Ramanan S; Grampp G
    BioDrugs; 2014 Aug; 28(4):363-72. PubMed ID: 24567263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mammalian cell culture capacity for biopharmaceutical manufacturing.
    Ecker DM; Ransohoff TC
    Adv Biochem Eng Biotechnol; 2014; 139():185-225. PubMed ID: 23748352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are biosimilars really generics?
    Misra A
    Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.